Aptevo Therapeutics Inc. APVO
1.08 USD -0.05 (-4.42%)
At closeNov 11, 2026, 4:00 AM EST
1.08 0.00 0.00%
Pre-market · Nov 11, 4:00 AM ET
1.07 Day range 1.14
1.07 52-week range 27.72
- YTD
- -88.55%
- 1 year
- -96.15%
News
benzinga.com Aptevo Therapeutics Announces Substantial Reduction In Infusion-Related Reactions For Mipletamig Following Successive Refinements To Its Priming-Dose Regimen; Improvement Builds On Mipletamig's Already Favorable Safety And Tolerability Profile The improvement builds on mipletamig's already favorable safety and tolerability profile, including encouraging cytokine release syndrome (CRS) findings observed throughout its clinical development.…
benzinga.com Aptevo Reports 10 AML Patients Advanced To Stem Cell Transplant Following Treatment With Mipletamig In Combination With Venetoclax And Azacitidine Ten patients initially deemed unfit for intensive chemotherapy proceeded to stem cell transplantTransplant rate compares favorably with historical standard-of-care experience, adding to growing…